NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc., a next-generation oncology therapeutics company, announced today the election of four external members to its Board of Directors: Axel Bolte; K. Peter Hirth, Ph.D; Thomas B. Neff and E. Jonathan Soderstrom, Ph.D. They join the company’s other directors: Arthur Altschul, Jr., Co-Founder and Chairman of the Board of Kolltan; Dr. Joseph Schlessinger, Kolltan’s Co-Founder and Chairman of the Scientific Advisory Board; and Kolltan’s Chief Executive Officer, Michael Schmertzler. In addition, Kolltan announced the appointment of Stanley Choy to the newly created position of Vice President Finance and Treasurer, and of W. Bradford Middlekauff to the newly created position of Chief Legal Officer, General Counsel and Secretary.
